Intra-Cellular Therapies Inc
ITCI
Market Cap$14B
Close$
$69.66
47.1% downside
Current Fair Value
47.1% downsideOvervalued by 47.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $14.00 Billion |
|---|---|
| Enterprise Value | $13.71 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.72 |
| Beta | 0.7 |
| Outstanding Shares | 103,131,017 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -181.81 |
|---|---|
| PEG | 444.34 |
| Price to Sales | 21.95 |
| Price to Book Ratio | 11.97 |
| Enterprise Value to Revenue | 20.14 |
| Enterprise Value to EBIT | -117.44 |
| Enterprise Value to Net Income | -184 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Intra-Cellular Therapies Inc
CEO: Sharon Mates